Peijia Medical’s TaurusElite Retrievable TAVR System Approved in China

July 29, 2021—Peijia Medical, a medical device company based in Suzhou, Jiangsu Province, China, recently announced that its TaurusElite transcatheter aortic valve replacement (TAVR) system was approved in late June for marketing by China’s National Medical Products Administration (NMPA). The approval will accelerate the transition of TAVR practice in China into the retrievable device era, stated the company.

According to Peijia Medical, the retrievable TaurusElite is the company’s second-generation TAVR system. The device’s design is similar to the TaurusOne, for which the company announced NMPA approval in April 2021.

TaurusElite uses bovine material for the prosthetic aortic valve. The device’s radial support and flexibility are ideal for China’s large cohort of patients experiencing high aortic valve calcification, bicuspid aortic valves, and other such lesions, noted Peijia Medical. The TaurusElite has an improved delivery system and enhanced axial support and flexibility for passing through the aortic arch. The device allows for repeated retrieval in situ or during high segment release, and transvalvular procedures permitted after retrieval.

Peijia Medical advised that academician Han Yaling, MD, of General Hospital of Northern Theater Command served as Coordinating Investigator for the TaurusElite TAVR System’s clinical trial that was completed by multiple organizations.